<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Pfizer-US7170811035">Pfizer</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">ETF Trends</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.etftrends.com/mailbag-follow-pfizer-other-questions/">Mailbag: A Follow-Up on Pfizer &amp; Other Questions</a>
    </div>

      <div class="me-0 me-md-5">
        Two weeks ago, I said that one of my favorite stocks right now is Pfizer (PFE). The pharmaceutical giant is in the middle of a transformational period with the goal to return to growth by 2029.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Pfizer-US7170811035">Pfizer</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260530351488/en/TALZENNA-Plus-XTANDI-Improves-Radiographic-Progression-Free-Survival-by-More-Than-50-in-Metastatic-Prostate-Cancer/">TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer</a>
    </div>

      <div class="me-0 me-md-5">
        NEW YORK--(BUSINESS WIRE)--TALAPRO-3 Data Presented at ASCO.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Pfizer-US7170811035">Pfizer</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260526978972/en/Seven-Year-Analysis-from-Pfizer%E2%80%99s-LORBRENA-CROWN-Trial-Shows-Longest-Progression-Free-Survival-Reported-to-Date-in-Advanced-Non-Small-Cell-Lung-Cancer/">Seven-Year Analysis from Pfizer&#39;s LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer</a>
    </div>

      <div class="me-0 me-md-5">
        NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced unprecedented seven-year follow-up results from the Phase 3 CROWN trial evaluating LORBRENA® (lorlatinib, a third-generation ALK inhibitor, available in Europe under the brand name LORVIQUA®) versus XALKORI® (crizotinib) in people with previously untreated, anaplastic lymphoma kinase (ALK)-positive advanced or metastatic non-sma...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Pfizer-US7170811035">Pfizer</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">CNBC</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.cnbc.com/2026/05/29/innovent-shares-rise-10percent-after-pact-with-pfizer-of-up-to-10point5-billion.html">Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion</a>
    </div>

      <div class="me-0 me-md-5">
        The partnership includes licensing, co-development, and co-commercialization opportunities across a diverse portfolio of antibody-drug conjugates. Innovent will will co-commercialize with Pfizer in the U.S. and Europe and share profits but retain rights in the Greater China market.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Pfizer-US7170811035">Pfizer</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/legal/litigation/chinas-innovent-biologics-pfizer-strike-up-105-billion-cancer-drug-deal-2026-05-28/">China&#39;s Innovent Biologics, Pfizer strike up to $10.5 billion cancer drug deal</a>
    </div>

      <div class="me-0 me-md-5">
        Chinese biopharmaceutical ​firm Innovent ‌Biologics and U.S. ​pharma ​giant Pfizer have ⁠struck a ​global ​licensing and collaboration deal worth ​up ​to $10.5 billion to ‌research ⁠and develop 12 early-stage ​cancer ​medicines, ⁠the companies ​said ​on ⁠Friday.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Pfizer-US7170811035">Pfizer</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/innovent-biologics-and-pfizer-enter-global-strategic-collaboration-to-accelerate-development-of-innovative-oncology-medicines-302785085.html">Innovent Biologics and Pfizer Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines</a>
    </div>

      <div class="me-0 me-md-5">
        SAN FRANCISCO and NEW YORK, and SUZHOU, China, May 28, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (01801.HK) and Pfizer Inc. (NYSE: PFE), today announced the companies have entered into a strategic global licensing and collaboration agreement for the research and development of 12 promising new breakthrough early-stage and de novo cancer medicines. The partnership includes licensing, co-deve...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Pfizer-US7170811035">Pfizer</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260527822150/en/Pfizer-and-Innovent-Biologics-Enter-Global-Strategic-Collaboration-to-Accelerate-Development-of-Innovative-Oncology-Medicines/">Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines</a>
    </div>

      <div class="me-0 me-md-5">
        NEW YORK &amp; SAN FRANCISCO &amp; SUZHOU, China--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Innovent Biologics, Inc. (01801.HK), today announced the companies have entered into a strategic global licensing and collaboration agreement for the research and development of 12 promising new breakthrough early-stage and de novo cancer medicines. The partnership includes licensing, co-development, and co-c...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Pfizer-US7170811035">Pfizer</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">4 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260527554283/en/Pfizer-Invites-Public-to-View-and-Listen-to-Webcast-of-Pfizer-Discussion-at-Healthcare-Conference/">Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference</a>
    </div>

      <div class="me-0 me-md-5">
        NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026 at 2:00 p.m. EDT. To view and listen to the webcast, visit our web site at www.pfizer.com/investors. Information o...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/en/news/Pfizer-US7170811035/load_more?page=9">
      Show more News
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>